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Abstract
The dimorphic fungus Candida albicans produces extracellular farnesol (3,7, 11-trimethyl-2,6,10-dodecatriene- 1-ol) which acts as a quorum-sensing molecule (QSM)
to suppress filamentation. Of four possible geometric isomers of farnesol, only the
E,E isomer possesses QSM activity. We tested 40 natural and synthetic analogs of
farnesol for their activity in an N-acetylglucosamine-induced differentiation assay
for germ tube formation (GTF). Modified structural features include the head group,
chain length, presence or absence of the three double bonds, substitution of a backbone carbon by S, O, N, and Se heteroatoms, presence or absence of a 3-methyl
branch, and the bulkiness of the hydrophobic tail. Of the 40 compounds, 22 showed
QSM activity by their ability to reduce GTF by 50%. However, even the most active
of the analogs tested had only 7.3% of the activity of E,E-farnesol. Structure-activity relationships were examined in terms of the likely presence in C. albicans of a
farnesol binding receptor protein.
Published in Chemistry & Biology 10 (August 2003), pp 743–750.
DOI 10.1016/S1074-5521(03)00158-3
Copyright © 2003 Elsevier Science Ltd. Used by permission.
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Introduction
The dimorphic fungus Candida albicans is the first eukaryotic system
shown to possess quorum-sensing behavior [1]. Quorum sensing has
been thoroughly described in prokaryotes but had not been demonstrated in eukaryotes until recently. With this phenomenon, a secreted
compound accumulates to a critical concentration in the medium
and then acts back on the producing cells to elicit a physiological response. For Gram-negative bacteria, the quorum-sensing molecules
are all members of a family of compounds known as acyl homoserine lactones [2]. In the case of C. albicans, the quorum-sensing molecule (QSM) is the sesquiterpene farnesol (3,7,11-trimethyl-2,6,10-dodecatriene-1-ol). Accumulation of farnesol blocks the morphological
shift from yeasts to mycelia [1]. Farnesol blocks germ tube formation
as triggered by serum, proline, or N-acetylglucosamine, and it is produced by and active on all (five) strains of C. albicans tested [1].
The effect of farnesol concerned morphological choice, not growth
rate. At concentrations of up to 250 μM, farnesol did not alter the
growth rate for C. albicans; actively budding yeasts were observed
in all cases [1]. This finding was confirmed by Ramage et al. [3] who
observed unimpaired growth rates up to 300 μM farnesol. The yeastmycelia transition is critical for pathogenicity, and C. albicans mutants limited to the yeast morphology are avirulent [4]. A follow-up
question based on this discovery is to identify farnesol’s mode of action in blocking germ-tube formation in C. albicans. One way of approaching this question is to design, prepare, and assay analogs of
farnesol with the expectation that comparison of the activity profiles
would identify essential and extraneous structural features. There is
also the possibility of synthesizing a compound with greater activity than that of farnesol. Analogs with enhanced activity could prove
useful in a clinical setting for prevention or prophylaxis of Candidiasis. This study looks at a series of first generation analogs of farnesol
and begins to uncover the biology of the quorum-sensing response
in Candida albicans as mediated by farnesol. To date, we have analyzed 40 analogs of farnesol. Of these, 22 show activity as determined
by their ability to reduce germ tube formation by at least 50% at concentrations up to 100 μM.
As well as gaining a better understanding of the biology of fungal quorum sensing, there are at least four practical advantages to
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be gained from farnesol analogs. (1) Preliminary experiments with
a mouse model show no obvious toxicity from farnesol. However, if
farnesol toxicity were to become a problem at higher dosages or with
prolonged treatment, it would be desirable to develop less toxic analogs that still maintain QSM activity. (2) Farnesol has limited water
solubility. Modifications of the structure of farnesol might lead to active compounds that were more soluble and thus more easily deliverable in animal systems. (3) Analogs of farnesol might also possess
improved pharmacokinetics, such as an enhanced ability to enter the
blood stream via the gastrointestinal tract or peritoneum. Alternatively, since farnesol is usually excreted from animals after its conversion to farnesoic acid and dicarboxylic acids [5], specific structural
changes may improve retention. Both scenarios could help maintain
the analog in an available form in the host. (4) While our in vitro studies suggest a possible prophylactic use for farnesol, it is still unclear
whether this will be seen in an animal model. Farnesol could prove to
act as a virulence factor for C. albicans. This question was posed by
Hornby et al. [1] based upon anticipated differences between in vitro
studies performed in a glass vessel and in vivo studies, where cellular membranes might act as a sink for the lipophilic farnesol. If farnesol functions as a virulence factor for C. albicans, it would be important to develop farnesol analogs that act as antagonists of virulence.
Results
Our previous work [1] reported that both commercial mixed isomers
farnesol and 96% E,E-farnesol exhibited QSM activity. However, subsequent comparisons with freshly opened bottles of farnesol showed
significantly greater activity with the E,E isomer (Table 1) and differing activities with mixed isomers farnesol from different suppliers (Table 1). Ninety-six percent E,E-farnesol reduced GTF to fifty percent at 1.2 μM, with complete inhibition at ca. 7.5 μM (Table 1) while
mixed isomers farnesol from Sigma (St Louis, MO) and Acros Organics (Pittsburgh, PAl reduced germ tube formation (GTF) to 50% at ca.
3.5 and 4.4 μM, respectively (Table 1). The three farnesol samples were
therefore analyzed by GCI MS. The lower activity Acros mixed isomers
farnesol contained only 33%-36% E,E-farnesol, whereas the higher activity Sigma mixed isomers farnesol contained 56% E,E-farnesol (Table
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Table 1. QSM Activity of Three Commercial Samples of Farnesol
				
Calculated
				
Concentration
		 Concentration Concentration
(μM) for 50% GTF
Percent
(μM) for
(μM) for
Based on Percent
Farnesol Source
E,E-Farnesola
0% GTFb
50% GTFb
E,E-Farnesolc
Sigma E,E-farnesol
Sigma mixed isomers
Across mixed isomers

96
56
36

7.5
25
30

1.2
3.5
4.4

1.2
2.1
3.2

a. Determined by GC/MS as previously described [1].
b. Based on the regression analysis as described in Experimental Procedures.
c. Calculated values of concentration that would be needed if all observed activity were due
to E,E-farnesol only, based on the known E,E-farnesol content of each sample.

1). There was sufficient E,E-farnesol in the two mixed isomers samples
to account for their QSM activities (Table 1). Based upon the percentage of E,E-farnesol in the Sigma and Acros Organics samples, reduction to 50% GTF would have been expected to occur at concentrations of 2.1 and 3.2 μM, respectively (Table 1). These concentrations
are lower than those determined experimentally for the mixed isomers
samples. Thus, it appears that only E,E-farnesol possesses QSM activity, and furthermore, a comparison of observed QSM activity (Table
1) with that predicted by the E,E-farnesol content suggests the other
isomers may even act to inhibit QSM activity.
Head Group Modifications
We tested six farnesol analogs with altered head groups (Table 2).
These modifications were introduced to learn whether farnesol’s C-1
hydroxyl was essential for QSM activity. An analog was considered to
be active if it was capable of reducing GTF by 50% at concentrations
of ≤100 μM. In practice, this definition meant that analogs were considered active if they had ≥1 % of the activity of E,E-farnesol. Farnesoic acid (analog 2, 3.3% relative activity) and the corresponding amide (3, 1.9%) maintained biological activity, whereas the aldehyde (4,
0.4%), bromide (5, 0.7%), methyl ester (6, 0.1 %), and amine (7, 0.1%)
were inactive (Table 2). The sulfhydryl analog was too insoluble to be
bioassayed. In particular, farnesoic acid, which has also been identified as a QSM produced by C. albicans [6], displayed only 3.3% of the
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Table 2. Biological Activity of Farnesol Analogs Based on Modified Head Groups

Analog 			
Number
X=
IC50 (μM)a
1
2
3
4
5
6
7

Relative
Activity

CH2OH (Farnesol)
1.2
100.0
COOH (Famesoic Acid)
36.2
3.26
CONH2
62.3
1.89
CHO (Farnesal) 		
0.38
CH2Br (Commercial E,E) 		
0.75
COOCH3		 0.10
CH2NH2 		
0.14

a. Inhibitory concentration (μM) at which germ tube formation is reduced to 50%.

activity exhibited by farnesol (Table 2). With regard to farnesol’s mode
of action, it is significant that the hydroxyl head group is not essential for QSM activity (Table 2). This conclusion is supported by the observation of Matsuoka and Oh that β-farnesene, with no functional
groups whatsoever, retained QSM activity [7].
Double Bond Modifications
We next examined five analogs based upon alterations of the 2,3 double bond in farnesol (Table 3). The 2,3 cyclopropane ring analog (8,
3.3%) maintained biological activity, whereas the 2,3 epoxide (9, 0.4%)
and 2,3 hydrogenated (10, 0.4%) analogs were inactive (Table 3). The
terminal 10,11 double bond was also essential for activity in that the
10,11 hydrogenated (11, 0.3%) and fully hydrogenated (12, 0.3%) analogs were inactive (Table 3). Not unexpectedly, all-trans retinol (vitamin A), a farnesol analog with five conjugated double bonds and a
bulky, cyclic tail group was also inactive (data not shown).
Sulfur-Containing Analogs
We next tested a series of 14 analogs that incorporated sulfur atoms in
place of a main chain CH2 unit (Tables 4 & 5). Seven of the eight analogs with a sulfur in the 4 position retained QSM activity (Table 4) including both the E- and Z- isomers of 4-thia farnesol (13, 3.7% and 14,
3.4%, respectively). Surprisingly, the 2,3 hydrogenated 4-thia analog
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Table 3. Biological Activity of Farnesol Analogs Based on Modifications to Their 2,3 Double Bond
Analog
Number

Double Bond 		
Modification
IC50 (μM)

Relative
Activity

1
8
9
10
11
12

None
1.2
2,3-cyclopropane
35.9
2,3-epoxide		
2,3-hydrogenated 		
10,11-hydrogenated 		
Hydrogenate all three double bonds 		

100.0
3.26
0.38
0.45
0.31
0.31

X=

27 		

68.7

1.72

28 		

23.2

5.08

29 		

24.4

4.80

(15, 7.3%) retained activity (Table 4), to the extent that it was ca. 16fold more active than the 2,3 hydrogenated analog (10) offarnesol itself (Table 3). The importance of the proximal 3-methyl side chain in
the 4-thia series was examined (Table 4) via comparison of the methylated compound 15 with the demethylated series represented by compounds 16 (3.7%), 17 (1.5%), and 18 (1.7%). All three demethyl analogs retained activity, as did the 3,4 disulfide (19, 1.6%). We can then
make the comparison among three compounds (17, 15, and 20 [0.5%])
with increasingly bulky 3-side chains (Table 4); activity increases 5-fold
with insertion of the 3-methyl (15 versus 17) and then decreases 16fold with the bulkier 3-ethyl (20 versus 15).
Similarly, five of the six analogs with the sulfur atom in the 9 position also retained QSM activity (Table 5). The 9-thia series with n-butyl
(21, 4.9%), isobutyl (22, 2.6%), and t-butyl (23, 0.9%) showed decreasing activity with increased branching (Table 5). The relative inactivity
of the t-butyI9-thia analog (23) should not be due merely to greater
hydrophobicity because the n-pentyl (24, 1.8%), benzyl (25, 1.7%), and
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Table 4. Biological Activity of Farnesol Analogs with Sulfur Atoms at the 4 Position

Analog 				
Number
X = 		
IC50 (μM)

Relative
Activity

13 		

(trans)

32.1

3.67

14 		

(cis)

35.1

3.36

15 			

16.0

7.34

16 			

31.6

3.70

17 			

79.1

1.47

18 			

67.0

1.75

19 		

72.4

1.61

20 				

0.48

(disulfide)

phenyl (26, 1.5%) 9-thia analogs still had QSM activity (Table 5). However, it could reflect the bulkier cross-section of the t-butyl being unable to fit into the narrow cleft of a farnesol receptor.
Chain Length Modifications
Farnesol is a 15 carbon sesquiterpene; it has a 12 carbon chain with
three methyl branches. We next examined whether altering the chain
length alters QSM activity. Three demethylated, 2,3-hydrogenated analogs (27, 1.7%; 28, 5.1%; and 29, 4.8%) have chain lengths of 10-12
carbons (Table 3) and lack the 2,3 double bond and 3-methyl branch
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Table 5. Biological Activity of Farnesol Analogs with Sulfur Atoms at the 9 Position

Analog 			
Number
X=
IC50 (μM)
21
22
23
24
25
26

n-butyl
23.8
Isobutyl
44.3
tert-butyl 		
n-pentyl
66.8
Benzyl
68.9
Phenyl
79.2

Relative
Activity
4.94
2.64
0.86
1.75
1.72
1.47

found in farnesol. Compounds 27-29 all exhibited activity, suggesting
some flexibility with regard to chain lengths. This flexibility with regard
to chain length was also shown by the 4-thia (Table 4) and 9-thia (Table 5) analogs. Counting S and –CH2– as equivalent, compounds 1618 in the 4-thia series (with chain lengths of 11-13, respectively) all
had QSM activity (Table 4) as did compounds 21 and 24 in the 9-thia
series (with chain lengths of 13-14, Table 5).
Heteroatoms in the Carbon Chain
Based on our success with the sulfur-containing analogs (Tables 4 and
5), we tried a series of other heteroatoms at the 4 and 9 positions (Table 6). The 4-Se analog (30, 2.6%) was the only one which retained
QSM activity; all the O-containing analogs and the one N-containing
analog (31,0.03%) were inactive (Table 6). In each case, the oxygencontaining analog was less active than the corresponding sulfur-containing analog. Compound 32 (0.1%) was 21-fold less active than 17,
compound 33 (0.5%) was 14-fold less active than 15, compound 34
(0.4%) was 4.6-fold less active than 18, and compound 35 (1.0%) was
2.8-fold less active than 22.
Hydroxyl and Epoxide Analogs of Farnesol
As seen in Table 3, the epoxide at the 2,3 position (9) was ca. 260-fold
less active than E,E-farnesol. However, the epoxide at the 10,11 position (36, 1.7%) was still active, as were the 10-hydroxyl (37, 1.7%) and
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Table 6. Biological Activity of Farnesol Analogs Containing Heteroatoms at the 4 or 9 Positions

Analog 			
Number
X=
IC50 (μM)
29
17
30
32
33
18
34
31

CH2
24.4
S
79.1
Se
45.7
O 		
O (with methyl branch 		
added back at 3-position)
SCH2–b
OCH2–b
NCH2–b

Relative
Activity
4.80
1.47
2.57a
0.07
0.51

X=

35 			

0.96

a. Compound 30 was 33% E and 67% Z at the 6,7-double bond. If only the E isomer was active, it would have a relative activity of 7.72.
b. 18, 31, and 34 have four carbons instead of three, between the head group hydroxyl and
the heteroatom.
c. Compounds 35 and 22 are identical except that 35 has 9-O while 22 has 9-S.

6-hydroxyl (38, 1.5%) analogs (Table 7). The 10,11 epoxide of farnesol is, of course, the reduced form of insect juvenile hormone III (39)
which has a methyl ester at the C-1 position instead of the hydroxyl
in farnesol. Thus, the QSM inactivity of juvenile hormone III (39) is expected from the inactivity of the corresponding methyl ester of farnesol (6, Table 2). Finally, in terms of designing a potential affinity column
for farnesol binding proteins, the omega-hydroxy 9-thia compound
(40, 0.1 %) was 49-fold less active than its nonhydroxylated parent
compound (21, Table 5). Similarly, all other farnesol analogs with a
terminal/ω-hydroxyl group were inactive (data not shown). Future
studies will be directed toward the design of an affinity column for
farnesol binding proteins.
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Table 7. Biological Activity of Hydroxy and Epoxide Analogs of Farnesol
Analog 			
Number 		
IC50 (μM)
1 		

Relative
Activity

1.2

100

2,3-epoxide 		
10,11-epoxidea
68.8
10-hydroxylb
68.5
6-hydroxylb
79.2
Juvenile Hormone III 0.16

0.38
1.72
1.72
1.47

40 			

0.10

9
36
37
38
39

a. Compound 36 is a modified (reduced) form of juvenile hormone III in which the carboxyl
group has been reduced to a primary alcohol.
b. Hydroxyls were introduced as racemic mixtures at the 10 (37) and 6 position (38) by hydroboration of the 10–11 and 6–7 double bonds, respectively.

Discussion
We have examined 40 natural and synthetic analogs of farnesol with
regard to their ability to block germ tube formation in Candida albicans. Twenty-two of the forty analogs exhibited QSM activity. Thus,
farnesol itself is not a requisite for QSM activity; there is flexibility
with regard to the head group (Table 2), double bonds (Table 3), chain
length (Tables 3 and 4), and the presence of sulfur and selenium heteroatoms in the farnesyl backbone (Tables 4-6). All of our assays involve adding analogs to cells programmed for GlcNAc-induced germ
tube formation. Thus, if we assume that there is an intracellular target/receptor for farnesol, the exogenous farnesol must cross the cytoplasmic membrane and then bind to the target. Therefore, the administered level of farnesol or farnesol analog may not reflect the
actual intracellular concentration available to the receptor or target.
As a corollary, a farnesol analog could be inactive either because it
has difficulty crossing the membrane or difficulty binding to the target. For instance, it is reasonable to suppose that the dihydroxy analog (40) and the analogs containing a basic nitrogen (7 and 31) might
have difficulty crossing the cytoplasmic membrane. Our focus on a
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putative farnesol binding protein is made with full realization that existing data do not yet prove the existence of farnesol binding proteins in C. albicans.
At present, virtually nothing is known about farnesol’s mode of action in regulating fungal cell morphology. One of the purposes in examining this collection of farnesol analogs was to put constraints on
the possible modes of action for farnesol. As a starting point, farnesol
could bind to a specific receptor. This receptor could be either a fungal analog of the nuclear FXR receptor found in most higher eukaryotes [8, 9] or a different farnesolspecific receptor. However, a genomic
search of S. cerevisiae and C. albicans failed to identify sequences similar to mammalian FXR receptors. Thus, if activity is mediated through
a farnesol receptor, it is likely to be of a type not previously observed.
What can we infer about the farnesol binding pocket of the putative receptor? How are conformational space and topographical space related to molecular recognition? One approach to our
structure-activity results is the linear approach based upon the three
regions of farnesol which are altered: (i) The C, terminal hydroxyl
group, (ii) the C1-C4 “head group” region, and (iii) the C9-C12 “tail” region. We have not yet analyzed enough analogs of the C5-C8 “midchain” region to draw any useful conclusions. In this regard, with the
exception of 30, the central double bond of all the analogs (equivalent to the 6,7 double bond of farnesol) retained the E configuration of the starting material (usually geranyl bromide or chloride). It
is tempting to suggest that the 6,7 double bond is critical for activity because compounds 13 (E) and 14 (Z), differing at the 2,3 double bond, had equivalent activities (Table 4).
The terminal hydroxyl group proved almost invariant. Although
farnesoic acid and the amide (2 and 3) displayed activity, functional
groups of similar size (aldehyde, methyl ester) or hydrogen-bonding
ability (amine) possessed no QSM activity. In this regard, the reduced
activity observed [1] for nerolidol (3,7, 11-trimethyl-1,6,10-dodecatriene-3-ol) could reflect either the altered regiochemistry or increased
steric bulk of the head group relative to the C1 primary hydroxyl of
farnesol. On the other hand, nerolidol differs from farnesol only in a
1,3-allylic transposition of the hydroxyl and alkene groups, and it is
possible that allylic isomerization to farnesol may be the source of the
“activity” of nerolidol.
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The rest of the head group region, however, proved fertile ground
for analog development. A primary alcohol was retained as a fixed
element in all designs. It is interesting to analyze the alkanol analogs
based on the assumption that the role of the farnesol C1-C4 region is
to hold the alcohol in a particular register relative to the remainder
of the molecule. The three-carbon span in 27 may be too short to allow the alcohol to occupy the same space as in farnesol, whereas the
four-carbon span in 28 can achieve a farnesol-like disposition through
a low-energy extended conformation and the longer five-carbon span
in 29 can adopt a similar overall shape through introduction of a single gauche kink. As a corollary, the inactivity of 10 suggests that the
presence of a C-3 methyl on the same five-carbon span prevents the
assumption of a farnesol-like conformation. The subtlety of these interactions is further illustrated by comparing removal of the 3-methyl
group for the all-carbon molecules (10 versus 29, 11-fold increase in
activity), the sulfur-containing analogs (15 versus 17, 5-fold decrease
in activity), and oxygen-containing analogs (33 versus 32, 7-fold decrease in activity).
The need for a tail region was clear from the complete lack of activity of the shorter (C10) geraniol [1]. Similarly, the lack of activity [1]
of the diterpene (C20) geranylgeraniol could represent “too much” tail
in terms of poor fit into a receptor or excess hydrophobicity. Replacement of the terminal 4-methyl-3-pentenyl unit of farnesol with an isobutyl ether (35) resulted in loss of activity, whereas the 10,11-epoxide
(36) and the 10-hydroxyl (37) analogs retained activity. Similarly, the
n-butyl and isobutyl thioethers (21 and 22) retained activity while the
inactivity of a tert-butyl thioether (23) suggested intolerance for steric bulk in the C9-C10 region.
A second approach to our structure-activity results is based on
the implications of substituting heteroatoms into the farnesol backbone. Most of the analogs containing a thioether retained QSM activity (Tables 4 and 5). The exact chain length did not appear to be
a critical variable. Compare the activities of 27-29 (Table 3) and 1618 (Table 4). In the latter series, 16, 17, and 18 had two-, three-, and
four-carbon spacers between the sulfur and the hydroxyl, respectively.
We note three points of interest in activity comparisons among four
pairs of molecules, 28 and 16, 29 and 17, 10 and 15, and 1 and 13/14,
which are identical except for the replacement of CH2 by sulfur. First,
for four compounds (13/14, 16, and 17) introduction of the sulfur
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atom decreases QSM activity relative to the carbon-containing analog, whereas 15 displays 16-fold greater activity than the nonsulfur
analog. Second, the mixed disulfide (19) also retains activity (Table 4).
Thus, we have a sequence of three active compounds (29, 17, and 19)
with nearly equivalent chain lengths but containing zero, one, and two
sulfurs, respectively. The final point of note is that compound 15 was
one of only nine analogs tested (8-10, 20, and 36-39 were the others) that possessed a chiral center. Compound 15 was prepared and
assayed as a racemic mixture; it is likely that one of the two enantiomers would possess even greater activity.
Thus, both the all-carbon alkanols (27-29) and the thiaalkanols (1618) retain significant activity. In theory, the corresponding O-ethers
should combine the best features of the alkanols (similar C-O and
C-C bond lengths) and the thiaalkanols (similar conformational preferences). However, none of the O-ethers had activity (Table 6). This
outcome may be due to the greater polarity of the ethers as well as
to an intramolecular H bond between the O-ether and the C-1 alcohol. This explanation is supported by a comparison between the inactive O-ether (32) and the highly active Se-ether (30). The results could
also reflect the relative C-X bond lengths: C-Se > C-S > C-C > C-O.
A third approach to our structure-activity results is based on the
role of alkenes in providing conformational constraints on the farnesol backbone. The three trisubstituted alkene subunits of farnesol
each impart significant conformational constraints on neighboring
linkages. In particular, allylic strain from the methyl groups at C3,
C7, and C11 precludes conformations which place the C1-O, C4-C5, or
C8-C9 bonds into juxtaposition with the methyl branches. Similarly,
1,2-strain disfavors conformations which juxtapose the C4-C5 or C8-C9
bonds with the C3 or C7 methyl branches, respectively. The importance of these alkene-induced conformational constraints may be reflected in the lack of activity of the 2,3-dihydrofarnesol (10) and the
2,3,6,7,10,11-hexahydro (saturated) farnesol (12). At the same time,
the results from the head and tail analogs demonstrate that neither
the C2-C3 nor C10-C11 double bonds are required for activity; structurally related thioethers retain activity (Tables 4 and 5). Given the juxtaposition of the activity retained by the thioethers versus that lost
by removal of the double bonds in compounds 10 and 12, one can
imagine three possible roles for the alkene units of farnesol: (i) fitting into a narrow cleft, (ii) precluding particular conformations and
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thereby organizing the main chain into the proper conformation for
binding, or (iii) providing electron density or van der Waals surface
for a particular interaction with the receptor.
Each of the ideas has attractive features, and of course, they are not
mutually exclusive. The first idea of a narrow cleft cannot be endorsed
or completely ruled out from our results. The epoxy (9) and cyclopropane (8) analogs preserve much of the conformational constraints of
the 2,3-alkene but significantly enlarge the cross-sectional area of the
alkene. The 2,3 cyclopropane analog maintains activity, but the more
polar 2,3 epoxide has lost activity (Table 3). The second idea in which
each of three trisubstituted alkenes exerts significant conformational
constraints on the surrounding region suggests an obvious role in
providing bias toward particular conformers. This hypothesis is supported by our discovery that the QSM activity of commercial farnesols correlates closely with the fraction of the natural E,E-isomer (Table
1). The third idea in which the alkene units provide needed electron
density fits with the strong activity of the thioethers. Replacement of
either the head (Table 4) or tail (Table 5) alkene with a straight chain
thioether maintains QSM activity. However, the activity of analogs containing linear methylene head groups (27–29) suggests that electron
density in the form of an alkene or a thioether is not essential. Thus,
in summary, the factors which seem necessary for farnesol’s QSM activity and binding to a presumptive farnesol binding protein include:
(i) a C-1 hydroxyl; (ii) a C-3 methyl group (but no larger); (iii) a hydrophobic tail; and (iv) the appropriate conformational constraints on
backbone conformers as provided by the three, trisubstituted alkenes
of farnesol. Factors which do not seem as critical include: (i) absolute
chain length; (ii) the chemical structure of the C9-C12 hydrophobic tail;
and (iii) the origin of the needed conformational constraints in the
backbone. S and Se heteroatoms are permitted.
Significance
Farnesol is a quorum-sensing molecule in Candida albicans that acts
to block the transition from yeasts to mycelia. It is widely agreed that
this morphological transition is a critical feature of this organism’s
pathogenicity. A further understanding of the action of farnesol on a
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molecular level could lead to better control of this common human
pathogen. To address this topic, we created a series of farnesol analogs and examined their ability to inhibit mycelial development. Taken
together, our results provide four major advancements to the understanding of the molecular action of farnesol. (1) Of the four possible
geometric isomers of farnesol, only the E,E isomer possesses QSM activity. (2) Structural analogs of farnesol that retain biological activity
can be synthesized. In other words, farnesol itself is not essential for
the activity seen in C. albicans. (3) Subtle changes in the structure of
farnesol lead to significant changes in the activity. (4) These analogs
indicate which parts of the molecule can be altered and still retain activity and which are essential for activity. This information may help in
the development of second generation farnesol analogs with useful
pharmacokinetic properties. For instance, studies using cyclization to
achieve conformational constraint seem indicated. However, even the
most active of the analogs tested had only 7.3% of the activity of E,Efarnesol, and thus they are unlikely to have any therapeutic potential
as farnesol agonists in hosts infected by C. albicans. However, if farnesol does prove to be a virulence factor for C. albicans, these analogs
may prove to be effective antagonists for farnesol.
Experimental Procedures
Strain and Chemicals
Candida albicans A72 was obtained from Patrick Sullivan, University of
Otago, Dunedin, New Zealand. A stock culture was grown in modified
glucose-salts-biotin medium, washed in potassium phosphate buffer,
and stored in the same buffer as previously described [1]. Commercial mixed isomers farnesol (Acros Organics and Sigma), E,E-farnesol
(Sigma), and farnesal (Pfaltz and Bauer, Waterbury, CT) were stored at
–20°C with desiccant. Juvenile Hormone III, E,E-farnesyl bromide, and
all-trans retinol (Sigma) were stored at –20°C. Our fresh farnesol samples were roughly ten times more active than those we had reported
previously [1], probably because this time we were scrupulous to exclude oxygen by resealing the pure farnesol oils under nitrogen and
storing them with desiccation.

Shchepin, Hornby et al. in Chemistry & Biology 10 (2003)

16

General Synthetic and Analytical Procedures
General procedures for synthesis and characterization of substrates
follow. Experimental procedures and characterization data for individual compounds are found in the accompanying appendix. All reagents
and solvents were used as supplied commercially, except tetrahydrofuran (THF; distilled from sodium/benzophenone), CH2CI2 (distilled from
CaH2), hexamethylphosphoric triamide (HMPA; distilled from CaH2 and
stored over 4 Å mol sieves), and N,N-dimethylformamide (DMF; stored
over 4 Å sieves). Unless otherwise noted, reactions were run under a
blanket of N2 in a round-bottom flask equipped with a magnetic stirrer. Except where noted, NMR spectra were taken as CDCI3 solutions at
300 MHz (1H) or 75 MHz (13C). Infrared spectra were acquired on neat
films on a ZrSe crystal. Purification of most compounds was based
upon air-driven (2-5 psi) flash chromatography on 230-400 mesh silica; the solvent system employed is listed for each compound. Thinlayer chromatography (TLC) employed silica (0.25 mm layer thickness) on glass plates; detection was accomplished with a hand-held
UV lamp, iodine vapor, 1% aqueous KMnO4 (alkenes), or charring with
a solution of ceric sulfate and ammonium molybdate in 10% H2SO4
(most compounds). Analytical and semipreparative HPLC employed
0.5 × 25 cm and 2.1 × 25 cm silica columns, with detection by refractive index. Mass spectra were obtained at the Nebraska Center for
Mass Spectrometry (Lincoln, NE). All prepared compounds were homogeneous by TLC, 1H NMR, and 13C NMR except for compound 30,
which was 33% trans and 67% cis at the 6,7 double bond.
Bioassays of Farnesol and Related Compounds
The bioassays were performed in 25 ml Erlenmeyer flasks in a differentiation medium consisting of 11 mM imidazole, pH 6.5, 3 mM
MgSO4, 2.6 mM N-acetyl-D-glucosamine (GlcNAc) as the germ tube
inducer, and either methanol (for a control) or a methanolic solution
of the compound being tested. All solutions of farnesol in methanol
were used immediately after preparation. Despite the fact that dilute
aqueous solutions of farnesol can be stable for years [1], pure farnesol oils are highly susceptible to air oxidation resulting in modification of the 10,11-alkene unit. Our assays of the 10,11-epoxide and the
10-hydroxyl compounds (Table 7) confirm that oxidative modification
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of the 10,11-alkene is accompanied by a dramatic decrease in QSM
activity. Prior to analysis, all compounds were dried, stored at 4°C for
no more than 24 hr, and resuspended as a 25 mM stock solution in
100% methanol immediately before use. The final concentration of
methanol in the bioassays was ≤1 %. All compounds were tested at 10,
50, and 100 μM for their ability to block germ tube formation. These
concentrations are well below the 250-300 μM levels at which farnesol itself does not impact the growth rate of C. albicans [1, 3]. Flasks
were preincubated at 37°C for 20 min and then inoculated to 5 × 106
cells/ml of C. albicans A72. Flasks were incubated at 37°C for 4 hr with
shaking at 250 rpm on a New Brunswick Scientific Co. G2 shaker. After 4 hr, cells were examined by phase-contrast microscopy. At least
100 cells were counted for every flask and analyzed for percent germ
tube formation. Compounds which exhibit farnesol-like activity cause
a shift from germ tubes to actively budding yeasts. Previous studies indicated that any lethal compounds or lethal concentrations instead gave phase dark, undifferentiated cells. None of analogs tested
exhibited toxicity at concentrations up to 100 μM.
Activity Calculations
Two measures of analog activity were employed. In the first, we compared the concentrations of farnesol and the analog necessary to
lower the percent germ tubes formed to 50%. An analog is considered to be active if it was capable of reducing germ tube formation
by 50% at the highest concentration tested. For inactive analogs, we
used an exponential decay function to model the activities of the
farnesol standard and the farnesol analogs according to the function
G = G0 × e(b×c), where G represents the percentage of germ tubes, C,
the concentration of sample in the assay, G0, the percentage of germ
tubes when C = 0, and b, the steepness of the decay. At zero concentration, 95%-99% mycelia were observed for all samples, and therefore, G0 was fixed at 95. This allowed a single parameter, b, to be determined by the least-squares method using the Maple V program
(Waterloo Maple, Waterloo, CAl. A commercial sample of E,E-farnesol (Sigma) was chosen as the standard. The percentage activity for
each analog was then determined by the ratio of the calculated b values from the regression algorithm. Results are presented in the tables
as “relative activity.”
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Supplemental Data — Experimental procedures and characterization (TLC, 1H and
13C NMR, and IR) for compounds 7, 11, 13-19, 21-23, 25, 27-35, and 37-38 can be
found at http://www.chembiol.com/cgi/content/full/10/8/743/DC1 ; references to
preparations of known compounds (3, 6, 8-10, 12, 26, and 36) are also provided.
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APPENDIX/SUPPORTING INFORMATION
Known Farnesol analogs: Eight of the farnesol analogs used in this work have been
synthesized and characterized previously. They are: compound 3, the farnesoyl amide,
see appendix reference #1 below; compound 6, the methyl ester of farnesoic acid, ref #2;
compound 8, 2,3-cyclopropane, ref #3; compound 9, 2,3-epoxide, ref #4; compound 10,
2,3-dihydro, ref #5; compound 12, perhydro, ref #6; compound 26, 8-phenylthiogeraniol,
ref #7; and compound 36, 10,11-epoxide, ref #8. In each case, the identities and purities
of the previously reported compounds were determined by 1H and 13C NMR. The other
farnesol analogs described below had not been previously reported. Compounds 1,2,4,5,
and 39 were purchased commercially.
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Previously unreported farnesol analogs
Farnesyl amine [(2E,6E)-3,7,11-trimethyldodecadienylamine] (compound 7): To the
solution of N-farnesyl trifluoroacetamide (0.7mmol) in THF (5mL) was added 6N NaOH
(3mmol). The solution was refluxed for 5 h. and then solvent was removed under
reduced pressure. The residue was diluted with water and extracted with CH2Cl2. The
organic layer was washed with water, dried over Na2SO4 and evaporated in vacuo to give
farnesylamine (95%): Rf=0.5 (10% NH3-saturated MeOH in CH2Cl2); 1H δ 1.33(s, 2H),
1.59(s, 6H), 1.62(s, 3H), 1.67(s, 3H), 1.96-2.10(m, 8H), 3.26(d, 2H, 6.9Hz), 5.09(m, 2H),

5.25(m, 1H); 13C NMR δ 15.96, 16.05, 17.63, 25.64, 26.40, 39.51, 39.61, 39.67, 124.00,
124.32, 125.87, 131.26, 135.13, 136.35; IR 2920, 1742,1563, 1440, 1291, 815 cm-1.
(2E,6E)-3,7,11-trimethyldodeca-2,6-dienol (compound 11): To a solution of 1-bromo3-methylbutane (10mmol) in dry THF (25mL) was added Mg (9mmol, turnings) and a
crystal of I2. The reaction was heated to reflux for 2 h (complete consumption of Mg),
cooled to -78°C and diluted with HMPA (3.5mL). A solution of (E)-8-bromogeranyl
acetate (1mmol) in THF (1mL) was added and the reaction was kept at -78°C for 2 h.
The reaction was then brought to room temperature and stirred for 10 h. Work-up as
before, followed by flash chromatography (20% EA/hex) afforded 10,11-dihydrofarnesol
in 60% yield: Rf=0.3 (20% EA/hex); 1H NMR δ 0.87(d, 6H, 7.2Hz), 1.12(m, 2H),
1.37(m, 2H), 1.52(m, 1H), 1.57(s, 3H), 1.67(s, 3H), 1.93(t, 2H, 7.5Hz), 2.05(m, 4H),
4.14(d, 2H, 6.9Hz), 5.08(m, 1H), 5.41(m, 1H);

13

C NMR δ 15.84, 16.22, 22.60, 25.70,

26.24, 27.84, 38.56, 39.55, 39.86, 59.33, 123.33, 123.45, 135.71, 139.71.
(2E)-4-thiafarnesol[(2E,6E)-3,7,11-Trimethyl-4-thia-2,6,10-dodecatrienol]
(compound 13) and (2Z)-4-thiafarnesol) [(2Z,6E)-3,7,11-Trimethyl-4-thia-2,6,10dodecatrienol] (compound 14): To a solution of (E)-geranyl thioacetate (3.7mmol) in
THF (15mL) was added MeONa (11.1mmol in 3mL of MeOH). After 30min, the reaction
was cooled to -78°C and ethyl 2-butynoate (4.44mol) was added drop wise via syringe.
After 10 h, the reaction was worked up as for the thioethers (e.g. compound 15) and
concentrated to furnish the alkenoate thioether as a crude oil, which was used without
further purification.
The oil was dissolved in THF (2ml), cooled down to -78°C and subjected to the
diisobutyl aluminum hydride (DIBAL) reduction (10mmol of 1.5M solution in toluene).

Following a standard work-up, the Z and E thioenol isomers were separated by flash
chromatography with 20% EA/hex to furnish 0.511g (50%) of the E-isomer (compound
13) and 0.128g (12%) of the Z isomer (compound 14).
(2E,6E)-3,7,11-trimethyl-4-thiadodeca-2,6,10-trienol (compound 13): Rf=0.3 (20%
EA/hex); 1H δ 1.42(s, 1H), 1.59(s, 3H), 1.68(s, 6H), 1.93(s, 3H), 2.03(m, 4H), 3.36(d,
2H, 7.2Hz), 4.19(d, 2H, 7.2 ), 5.07(m, 1H), 5.25(m, 1H), 5.43(m, 1H);

13

C δ 16.11,

17.63, 17.88, 25.61, 26.37, 29.39, 39.47, 59.22, 118.13, 120.72, 123.81, 131.67, 136.25,
140.17; IR 3347, 2952, 2929, 2871, 1454, 1060 cm-1.
(2Z,6E)-3,7,11-Trimethyl-4-thiadodeca-2,6,10-trienol (compound 14): Rf=0.4 (20%
EA/hex); 1H NMR δ 1.25(s, 1H), 1.59(s, 3H), 1.66(s, 6H), 2.04(m, 7H), 3.35(d, 2H,
7.5Hz), 4.27(d, 2H, 6.9Hz), 5.06(m, 1H), 5.21(m, 1H), 5.75(m, 1H); 13C δ 16.06, 17.65,
23.83, 25.62, 26.37, 29.04, 39.47, 59.97, 119.89, 123.79, 129.34, 131.68, 134.08, 139.34;
IR 3321, 2917, 1629, 1438, 1375, 1224, 1079, 1001, 836 cm-1.
Preparation of thioethers (compounds 15, 16, 17 and 18): Into a solution of
mercaptoalcohol (2mmol) in dry tetrahydrofuran (THF)(20mL) was added NaOH
(2mmol). The stirred solution was cooled to -78°C and (E)-geranyl chloride (1mmol) was
added via syringe. The reaction was allowed to warm to room temperature, and, after 12
h, concentrated under reduced pressure.

The residue was diluted with water and

extracted with 20% ethyl acetate/hexane (EA/hex). The organic layer was washed with
water, dried over Na2SO4 and concentrated under reduced pressure. The resulting oil was
purified by flash chromatography (10% EA/hex).
(E)-3,7,11-Trimethyl-4-thiododeca-6,10-dienol (compound 15): (95% yield); Rf=0.4
(20% EA/hex); 1H δ 1.30(d, 3H, 6.9Hz), 1.58(s, 3H), 1.66(s, 6H), 2.04(m, 5H), 2.87(m,

1H), 3.18(d, 2H, 7.5Hz), 3.76(m, 2H), 5.07(m, 1H), 5.24(m, 1H);

13

C δ 15.99, 17.62,

21.93, 25.61, 26.40, 28.01, 36.90, 39.10, 39.52, 60.86, 120.42, 123.89, 131.61, 138.72;
IR 3365, 2920, 1450, 1375, 1045, 994, 846 cm-1.
(E)-6,10-Dimethyl-3-undeca-5,9-dienol (compound 16): (93% yield); Rf=0.4 (20%
EA/hex); 1H δ 1.59(s, 3H), 1.64(s, 3H), 1.67(s, 3H), 2.05(m, 4H), 2.24(s, 1H), 2.67(t, 2H,
6Hz), 3.15(d, 2H, 7.8Hz ), 3.69(q, 2H, 5.7Hz), 5.06(m, 1H), 5.22(m, 1H);

13

C δ 15.99,

17.65, 25.64, 26.37, 28.72, 34.08, 39.54, 60.28, 120.20, 123.84, 131.71, 139.28; IR 3375,
2914, 1742, 1440, 1378, 1225, 1045, 830 cm-1.
(E)-7,11-Dimethyl-4-thiadodeca-6,10-dienol (compound 17):

(84% yield); Rf=0.4

(20% EA/hex); 1H δ 1.60(s, 3H), 1.65(s, 3H), 1.67(s, 3H), 1.76(s, 1H), 1.83(m, 2H),
2.05(m, 4H), 2.58(t, 2H, 7.2Hz), 3.16(d, 2H, 7.8Hz), 3.74(t, 2H, 5.7Hz), 5.08(m, 1H),
5.23(m, 1H); 13C δ 16.02, 17.65, 25.64, 26.42, 27.73, 29.26, 31.87, 39.55, 61.98, 120.34,
123.89, 131.65, 138.88; IR 3358, 2919, 1739, 1442, 1375, 1217, 1042 cm-1.
(E)-8,12-Dimethyl-5-thiotrideca-7,11-dienol (compound 18): (85% yield);

Rf=0.4

(20% EA/hex); 1H δ 1.51(s, 1H), 1.60-1.67(m, 13H), 2.04(m, 4H), 2.49(m, 2H), 3.14(d,
2H, 7.8Hz), 3.65(s, 2H), 5.07(m, 1H), 5.22(m, 1H);

13

C δ 15.97, 17.65, 25.64, 25.84,

26.42, 29.22, 30.67, 31.93, 39.55, 62.37, 120.53, 123.91, 131.59, 138.59; IR 3357, 2923,
1733, 1443, 1374, 1224, 1053 cm-1.
(E)-7,11-dimethyl-3,4-dithiododeca-6,10-dienol (compound 19):

To a solution of

geranyl thio acetate (0.5mmol) in 50:50 THF/MeOH was added NaOH (10mmol) and the
mixture was stirred for 30 min. Following addition of 2-mercaptoethanol (5mmol), the
solution was exposed to air for 10 h. Standard work-up followed by purification by flash
chromatography with 20% EA/hex afforded the mixed disulfide in 28mg (6%): Rf=0.5

(hexane); 1H NMR δ 1.60(s, 3H), 1.68(s, 3H), 1.70(s, 3H), 2.06(m, 5H), 2.85(t, 2H,
5.7Hz), 3.42(d, 2H, 8.1Hz), 3.88(quartet, 2H, 5.7Hz), 5.08(m, 1H), 5.28(m, 1H);

13

C

NMR δ 16.31, 17.66, 25.65, 26.31, 37.09, 39.61, 41.30, 60.28, 118.63, 123.75, 131.80,
141.48.
9-thia analogs (compounds 21-23 and 35)
(E)-8-hydroxygeranyl acetate: A solution of (E)-geranyl acetate (46mmol) and SeO2
(41mmol) in ethanol (70mL) was refluxed for 3h and then allowed to cool after which
NaBH4 (26mmol) was added. After 30 min, the reaction was filtered through a paper
filter and solvent was removed under reduced pressure. Work-up and chromatography
(20% EA/Hex) as above furnished 41% of (E)-8-hydroxygeranyl acetate along with 20%
of recovered starting material: Rf=0.4 (50% EA/hex); 1H NMR δ 1.61(s, 3H), 1.66(s, 3H),
2.00-2.11(m, 8H), 3.93(s, 2H), 4.53(d, 2H, 6.9Hz), 5.30(m, 2H);

13

C δ 13.5, 16.3, 20.9,

25.5, 38.9, 61.3, 68.3, 118.5, 124.9, 135.1, 141.6, 171.1.
(E)-8-bromogeranyl acetate: Into a -78°C solution of (E)-8-hydroxygeranyl acetate
(2mmol) and pyridine (2mmol) in THF (15mL) was added PBr3 (1mmol). The reaction
was allowed to warm to room temperature and stirred for 3 h. The reaction was then
quenched with 0°C sat. aq. NaHCO3 and extracted with 20% EA/hex. The crude allyl
bromide (estimated yield of 90%) was used directly for subsequent reactions.
9-thiafarnesol analogs (compounds 21, 22, and 23): To a solution of thiol (2.5mmol) in
THF (7mL) was added NaOH (1mmol) followed by (E)-8-bromogeranyl acetate
(0.5mmol in 0.5mL of THF). The mixture was stirred for 10 h whereupon 6N NaOH
(0.5mL) and H2O (3mL) were added. After stirring for 30 min., the reaction was worked

up as for other thioethers (e.g. compound 15). The oil was purified by flash
chromatography with 20% EA/hex to furnish the thioether.
(2E,6E)-3,7-Dimethyl-9-thiatridecadienol (compound 21): (89% yield); Rf=0.3 (20%
EA/hex); 1H NMR (500Mz) δ 0.90(t, 3H, 7.5Hz), 1.27(s, 1H), 1.38(m, 2H), 1.52(m, 2H,),
1.67(s, 3H), 1.70(s, 3H), 2.06(m, 2H), 2.16(m, 2H), 2.37(t, 2H, 7.5Hz), 3.07(s, 2H),
4.14(d, 2H, 6.5Hz), 5.22(m, 1H), 5.41(m, 1H); 13C NMR (125Mz) δ 13.70, 14.92, 16.17,
22.02, 26.28, 30.40, 30.89, 31.43, 39.28, 41.27, 59.31, 123.64, 127.26, 131.48, 139.20;
IR 3336, 2920, 1445, 1219, 1004 cm-1.
(2E,6E)-3,7,11-Trimethyl-9-thiadodecadienol (compound 22): (86% yield); Rf=0.3
(20% EA/hex); 1H NMR(500Mz) δ 0.96(d, 6H, 8.5Hz), 1.27(s, 1H), 1.66-1.76(m, 7H),
2.07(m, 2H), 2.15(m, 2H), 2.25(d, 2H, 8.5Hz), 3.05(s, 2H), 4.15(d, 2H, 5Hz), 5.21(m,
1H), 5.41(m, 1H);

13

C NMR(125Mz) δ 14.92, 16.19, 22.05, 26.29, 28.28, 39.29, 39.90,

41.80, 59.33, 123.64, 127.34, 131.55, 139.23.
(2E,6E)-3,7,10,10-Tetramethyl-9-thiaundecadienol (compound 23): (91% yield);
Rf=0.4 (20% EA/hex); 1H NMR δ 1.32(s, 9H), 1.60(s, 1H), 1.66(s, 3H), 1.72(s, 3H),
2.06(m, 2H), 2.13(m, 2H), 3.17(s, 2H), 4.14(d, 2H, 9Hz), 5.54(m, 1H), 5.41(m, 1H); 13C
δ 15.52, 16.13, 26.24, 30.85, 38.27, 38.98, 42.35, 59.33, 123. 76, 127.13, 132.10, 139.16.
(E,E)-3,7,11-Trimethyl-9-oxadodeca-2.6-dienol (compound 35): (92% yield); To the
suspension of NaH (3mmol, 60% dispersion in mineral oil) in THF (10mL) was added
isobutyl alcohol (10mmol) followed by (E)-8-bromogeranyl acetate (0.5mmol in 0.5mL
of THF). After 10 h, 6N NaOH (0.5mL) and H2O (3mL) were added and the reaction
was stirred for 30 min. Work-up as before furnished 0.104g (92%) of the ether as an oil:
Rf=0.3 (20% EA/hex);

1

H NMR δ 0.91(d, 6H, 6Hz), 1.23(s, 1H), 1.64(s, 3H), 1.69(s,

3H), 1.86(m, 1H), 2.03-2.23(m, 4H), 3.12(d, 2H, 6Hz), 3.83(s, 2H), 4.15(d, 2H, 6.4Hz),
5.34(m, 2H); 13C NMR δ 14.5, 17.0, 20.1, 26.7, 29.2, 39.8, 60.1, 77.4, 77.6, 124.4, 127.6,
133.8, 140.0. IR 3375, 2920, 1460, 1086, 1004 cm-1.
Alkanol analogs (compounds 27-29).
(E)-5,9-Dimethyldeca-4,8-dienol (compound 27): Compound 27 was prepared from
(E)-geranyl chloride and vinyl magnesium bromide by a two step procedure similar to
that used for compound 19. The initial product was (E)-5,9-dimethyldeca-1,4,8-triene (124): Rf=0.9 (hexane); 1H NMR δ 1.62(s, 6H), 1.7(s, 3H), 2.76(t, 2H, 6.6), 4.94-5.18(m,
4H), 5.81(m, 1H). Hydroboration of the triene as described above furnished compound
20 in 57% (two steps): Rf=0.3 (20% EA/hex); 1H δ 1.48(s, 1H), 1.57-1.67 (m, 11H),
2.06(m, 6H), 3.63(t, 2H, 6.6Hz), 5.12(m, 2H);

13

C NMR δ 15.91, 17.63, 24.23, 25.65,

26.61, 32.70, 39.67, 62.68, 123.73, 124.23, 131.40, 135.77; IR 3339, 2919,1736, 1450,
1214, 1050 cm-1.
(E)-6,10-Dimethylundeca-5,9-dienol (compound 28): (E)-geranyl chloride (3mmol)
was added drop-wise via syringe into a -78°C solution of allyl magnesium chloride
(7.5mmol, 2M solution in THF) and hexamethylphosphoric triamide (HMPA)(1mL) in
THF (6mL). The reaction was allowed to warm to room temperature, and after 12 h,
quenched with water. The pentane extract was washed with water, dried over Na2SO4 and
concentrated by evaporation at normal pressure. The resulting oil was purified by flash
chromatography with pentane to furnish (E)-6,10-dimethylundeca-1,5,9-triene (1-22) in
67% yield: Rf=0.9 (hexane); 1H 1.62(s, 6H), 1.70(s, 3H), 1.99-2.12(m, 8H), 4.94-5.18(m,
4H), 5.84(m, 1H).

9-BBN (9-borabicyclononane) (2mmol, 0.5M solution in THF) was added to a
solution of the triene (estimated 2mmol) in THF (15mL). After 5 h, the reaction was
quenched by the successive addition of ethanol (2mL), 6N aq. NaOH (3mmol), and 30%
H2O2 (4mmol). The mixture was diluted with water and extracted with 20% EA/hex.
Work-up as before and purification by flash chromatography with 20% EA/hex furnished
the alcohol in 53% yield over two steps. Rf=0.4 (20% EA/hex); 1H NMR δ 1.40(m, 3H),
1.59(m, 8H), 1.60(s, 6H), 1.68(s, 3H), 2.00(m, 6H), 3.64(t, 2H, 6.6Hz), 5.10(m, 2H); 13C
δ 15.96, 17.65, 25.67, 25.90, 26.67, 27.55, 32.32, 39.70, 64.97, 124.23, 124.32, 131.30,
135.29; IR 3331, 2922, 2922, 1443, 1373, 1058 cm-1.
(E)-7,11-Dimethyldodeca-6,10-dienol (compound 29):

A solution of 4-bromo-1-

butene (30mmol) in THF (17mL) was refluxed for 3 h over Mg (30 mmol) until the
turnings were consumed. The resulting solution was cooled to -78°C and diluted with
HMPA (2.5mL). Addition of (E)-geranyl bromide (3mmol), followed by work-up and
purification as above afforded (E)-6,10-dimethyldeca-1,6,10-triene (1-30): Rf=0.9
(hexane); 1H δ 1.43(m, 2H), 1.60(s, 6H), 1.69(s, 3H), 2.04(m, 6H), 4.92-5.13(m, 4H),
5.81(m, 1H).
Hydroboration as before furnished dienol compound 29 in 42% yield over two
steps: Rf=0.5 (20% EA/hex); 1H δ 1.31(s, 1H), 1.35(m, 4H), 1.59(m, 8H), 1.68(s, 3H),
2.00(m, 6H), 3.63(t, 2H, 6.3Hz), 5.11(m, 2H);

13

C δ 15.94, 17.65, 25.33, 25.67, 26.72,

27.79, 29.60, 32.71, 39.70, 63.03, 124.35, 124.43, 131.26, 135.0; IR 3335, 2926, 2852,
1447, 1377, 1054 cm-1.
7,11-Dimethyl-4-selenadodeca-6,10-dienol (compound 30): To a -78°C solution of
KSeCN (2.2mmol) in THF (10mL) was added the tetrahydropyranyl ether of 3-

bromopropanol (2mmol). After stirring for 10h, the reaction was diluted with water and
extracted with pentane. The organic layer was washed with water, dried over sodium
sulfate and evaporated in vacuo to give the selenocyanate which was used without further
purification. Into a -78°C THF solution of the selenocyanate was successively added
NaBH4 (4mmol), ethanol (1mL) and (E)-geranyl chloride (1mmol). The reaction was
warmed to room temperature and stirred for 10 h. Following work-up as before, the
crude residue was treated with 100mg of pyridinium p-toluenesulfonate in 5ml MeOH for
7 h. Concentration, followed by flash chromatography with 20% EA/hex, afforded the
selenoether (0.215 g, 78%) as a 32:67 mixture of Z:E isomers according to GC/MS
(retention times 16.98:17.28 min.): Rf=0.4 (20% EA/hex); 1H (mixture of E and Z
isomers) δ 1.57-1.71(m, 9H), 1.89(p, 2H, 6.6Hz), 2.04(m, 5H), 2.58(m, 2H), 3.20(d, 2H,
8.4Hz), 3.69(t, 2H, 6.3Hz), 5.05(m, 1H), 5.31(m, 1H);

13

C NMR(mixture of E and Z

isomers) δ 15.77, 17.59, 19.44, 19.83, 20.70, 23.25, 25.58, 26.41, 26.49, 31.61, 32.92,
39.41, 39.51, 62.37, 62.43, 120.93, 121.58, 123.79, 123.85, 131.55, 131.84, 138.29,
138.38: FAB-MS: M/Z(M+Li)+=283.1
(E)-8,12-Dimethyl-5-azatrideca-7,11-dienol (compound 31): To a solution of 4aminobutanol (2mmol) in THF (15mL) was added NaHCO3 (5mmol) and (E)-geranyl
bromide (1mmol). After stirring for 10 h., the reaction mixture was found to still contain
unreacted geranyl bromide and was heated to reflux for 2 h. Work-up as before followed
by flash chromatography with a 10% solution of sat. NH3/MeOH in CH2Cl2 furnished
0.025g (11%) of the desired secondary amine along with 0.1516g (42%) of the tertiary
amine byproduct. Rf=0.2 (10% of sat. NH3/MeOH in CH2Cl2); 1H δ 1.58-1.66(m, 13H),
2.02(m, 4H), 2.64(t, 2H, 5.7Hz), 3.23(d, 2H, 6.9Hz), 3.33(s, 3H), 3.57(t, 2H, 4.5Hz),

5.06(m, 1H), 5.24(m, 1H);

13

C δ 16.19, 17.65, 25.64, 26.42, 28.53, 32.39, 39.57, 46.49,

48.79, 62.46, 121.35, 123.95, 131.58, 138.94.
Preparation of ethers (compounds 32 and 34): The diol (7mmol) was added to a stirred
suspension of NaH (3mmol as 60% dispersion in mineral oil) in distilled THF (20mL).
The mixture was stirred for 20 minutes. (E)-geranyl bromide (1mmol) was added drop
wise via syringe and the reaction was refluxed for 4 h. Work-up as above followed by
flash chromatography (20% EA/hex) furnished the ether.
(E)-7,11-Dimethyl-4-oxadodeca-6,10-dienol (compound 32): (72% yield); Rf=0.3
(20% EA/hex); 1H δ 1.59(s, 3H), 1.65(s, 3H), 1.67(s, 3H), 1.82(pentet, 2H, 5.7Hz),
2.04(m, 4H), 2.52(s, 1H), 3.60(t, 2H, 5.7Hz), 3.76(t, 2H, 5.4Hz), 3.98(d, 2H, 6.9Hz),
5.07(m, 1H), 5.32(m, 1H);

13

C δ 16.38, 17.62, 25.62, 26.28, 32.03, 39.51, 62.01, 67.54,

69.21, 120.59, 123.87, 131.64, 140.34.
(E)-8,12-Dimethyl-5-oxatrideca-7,11-dienol (compound 34): (76% yield); Rf=0.3
(20% EA/hex);

1

H δ 1.59(s, 3H), 1.67(m, 10H), 2.04(m, 4H), 2.58(s, 1H), 3.45(t, 2H,

6Hz), 3.62(d, 2H, 5.4Hz), 3.98(d, 2H, 6.6Hz), 5.08(m, 1H), 5.33(m, 1H);

13

C δ 16.37,

17.62, 25.62, 26.31, 26.93, 30.34, 39.54, 62.68, 6729, 70.00, 120.52, 123.91, 131.61,
140.33; IR 3396, 2920, 2858, 1445, 1373, 1102, 1061 cm-1.
(E)-3,7,11-trimethyl-4-oxydodeca-6,10-dienol (compound 33): A suspension of NaH
(4.5mmol, 60% dispersion in mineral oil) was washed with hexane (2 x 0.3mL each),
after which was added 3-butene-2-ol (4.5mmol) in 15mL of dry THF followed by (E)geranyl bromide (1.5mmol). The reaction was heated to reflux for 10h and then cooled.
Solvent was removed at the reduced pressure, and the residue was diluted with water.
The pentane extract was dried with Na2SO4 and evaporated at normal pressure to give a

crude oil. Without further purification the crude material was dissolved in THF (5mL)
and 9-BBN (9-borabicyclononane, 1.5mmol) was added. After 10 h., the reaction was
quenched by the successive addition of ethanol (2mL), 6N NaOH (3mmol), and 30%
H2O2 (4mmol). Following work-up as for compound 26, chromatography (20% EA/Hex)
furnished the ether in 84% yield over two steps: Rf=0.3 (20% EA/hex);

1

H NMR δ

1.18(d, 3H, 6Hz), 1.59(s, 3H), 1.66-1.77(m, 8H), 2.04(m, 4H), 2.81(s, 1H), 3.75(m, 3H),
3.93(m, 1H), 4.08(m, 1H), 5.07(m, 1H), 5.32(m, 1H);

13

C δ 16.37, 17.63, 19.45, 25.64,

26.29, 38.64, 39.52, 61.22, 64.74, 74.67, 120.84, 123.89, 131.65, 140.24; IR 3411, 2925,
1454, 1050 cm-1.
(2E,6E)-3,7,11-trimethyldodecadiene-1,10-diol

and

(2E)-3,7,11-trimethyldodeca-

2,10-diene-1,6-diol (compounds 37 and 38): Into a solution of farnesol (1mmol) in THF
(10mL) was added 9-BBN (9-borabicyclononane, 2mmol). The reaction was stirred for
10 h and then quenched by the successive addition of ethanol (2mL), 6N NaOH (3mmol),
and 30% H2O2 (4mmol). The resulting mixture was readily separated by flash
chromatography (50% EA/hex) to afford 90% of recovered farnesol, 0.096g of 10hydroxyfarnesol and 0.144g of 6-hydroxyfarnesol.
(2E,6E)-3,7,11-Trimethyldodecadiene-1,10-diol

(compound

37):

Rf=0.5

(50%

EA/hex); 1H NMR δ 0.89(d, 6H, 6.6Hz), 1.47-1..66(m, 9H), 2.03-2.19(m, 6H), 3.35(m,
1H), 4.10(d, 2H, 6.9Hz), 5.16(m, 1H), 5.39(m, 1H);

13

C NMR δ15.76, 17.34, 18.67,

25.64, 30.88, 31.23, 33.53, 36.69, 39.23, 59.20, 76.85, 124.24. 124.78, 135.96, 138.74;
IR 3334, 2920, 1670, 1445, 1378, 999 cm-1. FAB-MS: M/Z(M+Li)+=247.2.
(2E)-3,7,11-Trimethyldodeca-2,10-diene-1,6-diol (compound 38): Rf=0.4 (20%
EA/hex); 1H NMR δ 0.89(d, 3H, 6.6Hz), 1.24(m, 2H), 1.51(m, 2H), 1.59(s, 3H), 1.68(m,

6H), 1.35-2.28(m, 5H), 3.44(m, 1H), 4.14(d, 2H, 6.9Hz), 5.09(m, 1H), 5.44(m, 1H); 13C
NMR δ 15.04, 16.24, 17.63, 25.64, 25.68, 31.14, 32.04, 36.16, 38.45, 59.26, 75.59,
123.59, 124.55, 131.51, 139.74; IR 3339, 2920, 2366, 2366, 1455, 1383, 999 cm-1. FABMS: M/Z(M+Li)+=247.2.

